Please assess the completion status of the following clinical trial:

Trial Title: A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent of parent(s) or legally acceptable representative of subject and child assent, as appropriate obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~* Male or female, ages 12 to below 18 years at the time of signing informed consent~* BMI equal to or above 95th percentile OR equal to or above 85th percentile (on gender and age-specific growth charts (CDC.gov)) with 1 or more weight related comorbidity (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes~* History of at least one self-reported unsuccessful dietary effort to lose weight~For subjects with type 2 diabetes at screening the following inclusion criteria apply in addition:~- HbA1c equal to or below 10.0% (86 mmol/mol) as measured by central laboratory at screening~Exclusion Criteria:~* Prepubertal subjects (Tanner stage 1)~* History of type 1 diabetes~* A self-reported (or by parent(s)/legally acceptable representative where applicable) change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records~* Subjects with secondary causes of obesity (i.e., hypothalamic, monogenic or endocrine causes)~* For subjects with type 2 diabetes only: Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): 2.4 mg or maximum tolerated dose (MTD) injected subcutaneously (under the skin, s.c.) once weekly
- Placebo (Type: PLACEBO_COMPARATOR): Placebo injected s.c. once weekly .

Based on this trial design, predict the completion outcome and termination type (if applicable).